Posts by Mourabit Halima

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. For patients with unresectable HCC, transarterial chemoembolization (TACE) is a standard treatment. The phase 2, multicenter, open-label, randomized CARES-005…

Editor's Note: Refractory cancer pain often responds poorly to standard pain management strategies. Both in vitro and in vivo studies have shown that hawthorn standardized extract (HSE) possesses central and…

At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her…

At the San Antonio Breast Cancer Symposium 2024, Dr. Charles Geyer, Jr. presented important research focused on improving treatment strategies for triple-negative breast cancer (TNBC). His work continues to drive…

The five-year follow-up data from CheckMate 649, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, confirms the long-term survival benefits of nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction, and…

A systematic review and meta-analysis, published in The Lancet Oncology, provides new insights into which patients benefit most from adding docetaxel to androgen deprivation therapy (ADT). The data, pooled from…

In a significant advancement in cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial" in JAMA Oncology on April, 2024. This pivotal study investigates the efficacy and safety of MW032, a proposed denosumab biosimilar, in treating solid tumor-related bone metastases. Bone metastases, a common and severe complication in cancer patients, lead to skeletal-related events (SREs) that significantly impact morbidity and mortality. The study addresses the urgent need for more effective and accessible treatments for patients suffering from these severe complications.

Editor's Note: In this exclusive interview, we speak with Dr. Anna Dorothea Wagner, a leading expert in gastrointestinal oncology, about the evolving landscape of virtual targeted diagnosis and treatment for…

Editor's note: The LAPIS Phase 3 trial was a large-scale, global, double-blind, placebo-controlled study designed to assess the efficacy of pamrevlumab in combination with chemotherapy for patients with locally advanced…